ClinicalTrials.gg
CompletedNCT02483208Updated Feb 17, 2016

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

A Phase 1 interventional study of BAY81-8973 and Advate in Hemophilia A, sponsored by Bayer. Completed at 1 site in Bulgaria. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-02-17.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
16th of 21
18 · median 50
Started
2015
with 1 other
Phase 1
3 of 21
none open now
Registered
17th of 21
by date
Lead sponsor
3 of 21
Bayer

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 16th largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 1, and was the 17th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The purpose of this study is to compare the pharmacokinetics of BAY81-8973 and Advate after intravenous administration.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males, age 18 to 65 years

    • Subjects with Severe hemophilia A with a documented plasma FVIII level of \<1%
    • ≥ 150 exposure days with FVIII concentrate(s) as supported by medical records

Exclusion criteria

Exclusion Criteria:

  • Evidence of current or past inhibitor antibody

    • History of any congenital or acquired coagulation disorders other than hemophilia A
    • count \<75,000/mm3
    • Abnormal renal function (serum creatinine >2 times the [ULN] range)
    • Active liver disease verified by medical history or persistently elevated (ALT) or aspartate aminotransferase (AST) >5 times the ULN or severe liver disease as evidenced by, but not limited to any of the following: (INR) >1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    BAY81-8973

    BAY81-8973 infusion to analyze pharmacokinetics

    Drug: BAY81-8973

  • Other
    Advate

    Advate infusion to analyze pharmacokinetics.

    Drug: Advate

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-tlast)

    Area under the blood concentration vs time curve from zero to the last data point \> lower limit of quantification

    Time frame: Pre-Dose, 0.25, 0.5, 1, 3, 6, 8, 24, 30, 48 hours after treatment

07

Study locations

1 site
  • Sofia, 1756, Bulgaria
08

References and documents

Publications

  • Shah A, Solms A, Garmann D, Katterle Y, Avramova V, Simeonov S, Lissitchkov T. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. Clin Pharmacokinet. 2017 Sep;56(9):1045-1055. doi: 10.1007/s40262-016-0492-2. PubMed 28005225 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Jul 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2015
First posted
Jun 26, 2015
Start
Jun 2015
Primary completionActual
Jul 2015
CompletionActual
Dec 2015
Last update
Feb 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02483208
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 26, 2015
Start date
Jun 2015
Primary completion
Jul 2015
Completion
Dec 2015
Last update
Feb 17, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human

Start the discussion